GALVmed has received funding approval totalling to US$ 19 million for the Phase 3 programme on Improved Tools for the Control of Animal African Trypanosomosis (Tryps 3). The main objective of the programme, which is co-funded by the UK Government and Bill & Melinda Gates Foundation, is to commercially develop a registered therapeutic trypanocidal product […]